昭衍新药(603127)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

603127 昭衍新药

午间休市 05-06 11:29:59

{"stockData":{"symbol":"603127","market":"SH","secType":"STK","nameCN":"昭衍新药","latestPrice":18.03,"timestamp":1714966199000,"preClose":16.39,"halted":0,"volume":39856031,"delay":0,"floatShares":630000000,"shares":750000000,"eps":-0.084,"marketStatus":"午间休市","marketStatusCode":3,"change":1.64,"latestTime":"05-06 11:29:59","open":16.3,"high":18.03,"low":16.3,"amount":700000000,"amplitude":0.1056,"askPrice":0,"askSize":0,"bidPrice":18.03,"bidSize":72415,"shortable":0,"etf":0,"ttmEps":-0.084,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714971600000},"adr":0,"adjPreClose":16.39,"symbolType":"stock","openAndCloseTimeList":[[1714959000000,1714966200000],[1714971600000,1714978800000]],"highLimit":18.03,"lowLimit":14.75,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":749888699,"pbRate":1.54,"roa":"--","roe":"--","epsLYR":0.53,"marketValue":13520000000,"floatMarketCap":11368000000,"peRate":-214.64286,"changeRate":0.1001,"turnoverRate":0.0632,"status":0},"requestUrl":"/m/hq/s/603127/","defaultTab":"news","newsList":[{"id":"2433460024","title":"昭衍新药、康龙化成涨超6%：港股医药股整体上涨，CXO方向表现突出","url":"https://stock-news.laohu8.com/highlight/detail?id=2433460024","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2433460024?lang=zh_cn&edition=full","pubTime":"2024-05-06 10:41","pubTimestamp":1714963305,"startTime":"0","endTime":"0","summary":"快讯正文5月6日，港股医药股整体表现强势，创新药及CXO概念股领涨。其中，CXO板块异常活跃，昭衍新药、康龙化成、药明生物和泰格医药涨幅超过6%，金斯瑞涨幅超过5%，凯莱英涨势强劲，上涨近5%，药明康德则涨超3%。在当前医药行业的快速发展背景下，这些CXO概念股的优异表现，无疑为投资者提供了新的投资机会。CXO即合同研发、生产和销售服务，近年来随着医药行业的发展，CXO行业也呈现出快速发展的态势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050610530087d685ee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050610530087d685ee&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2433046795","title":"医疗，再度冲高！医疗ETF（512170）大涨超3%，强势站上60日均线！昭衍新药涨停，巨头药明康德劲涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2433046795","media":"新浪基金","top":-1,"share":"https://www.laohu8.com/m/news/2433046795?lang=zh_cn&edition=full","pubTime":"2024-05-06 10:19","pubTimestamp":1714961940,"startTime":"0","endTime":"0","summary":"　　医疗，继续上攻！5月6日早盘，医疗板块再发力，场内热门医疗ETF跳空高开，截至发稿涨3.27%，强势站上60日均线！　　成份股方面，医疗服务、医疗器械携手上涨，昭衍新药涨停！通策医疗飙涨超8%，CXO巨头药明康德、医美龙头爱美客双双涨超5%！风险提示：医疗ETF及其联接基金被动跟踪中证医疗指数，该指数基日为2004.12.31，发布于2014.10.31，指数成份股构成根据该指数编制规则适时调整。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/money/fund/etf/2024-05-06/doc-inaufyzf1688005.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2024-05-06/doc-inaufyzf1688005.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2433246264","title":"异动快报：昭衍新药（603127）5月6日10点9分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2433246264","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2433246264?lang=zh_cn&edition=full","pubTime":"2024-05-06 10:10","pubTimestamp":1714961430,"startTime":"0","endTime":"0","summary":"证券之星5月6日盘中消息，10点9分昭衍新药触及涨停板。目前价格18.03，上涨10.01%。其所属行业医疗服务目前上涨。领涨股为通策医疗。该股为健康中国，创新药，医药概念热股，当日健康中国概念上涨2.97%，创新药概念上涨2.01%，医药概念上涨1.93%。4月30日的资金流向数据方面，主力资金净流出5867.6万元，占总成交额10.31%，游资资金净流入114.07万元，占总成交额0.2%，散户资金净流入5753.54万元，占总成交额10.11%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050600003834.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2433461550","title":"生物疫苗概念盘中拉升，昭衍新药涨5.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2433461550","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2433461550?lang=zh_cn&edition=full","pubTime":"2024-05-06 09:43","pubTimestamp":1714959813,"startTime":"0","endTime":"0","summary":"05月06日，生物疫苗概念盘中拉升，截至09点43分，生物疫苗概念整体指数上涨0.68%，报1992.150点。从个股上来看，该概念的成分股中，昭衍新药涨5.92%，康希诺、西藏药业2只股涨幅超过5%。从资金上来看，截止发稿，生物疫苗概念主力净流入为-460.24万，其中智飞生物受到资金热捧，主力净流入1473.80万；拉长时间线来看，该板块近20日主力资金净流入-27.31亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240506094333861eb034&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240506094333861eb034&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2433461463","title":"昭衍新药大幅上涨 科创板创新药企业发展向好","url":"https://stock-news.laohu8.com/highlight/detail?id=2433461463","media":"智选洞察","top":-1,"share":"https://www.laohu8.com/m/news/2433461463?lang=zh_cn&edition=full","pubTime":"2024-05-06 09:33","pubTimestamp":1714959190,"startTime":"0","endTime":"0","summary":"消息解读此外，科创板是美国、中国香港之外的全球生物医药企业主要上市地，已汇聚约三十余家创新药企业，重点介入癌症、艾滋病、乙肝、丙肝等治疗领域。在政策暖风下，科创板创新药板块整体发展态势持续向好。中国在光伏、动力电池、电动车、智能驾驶等科技赛道上已经做到了世界领先，未来有望在半导体、高端制造、创新药、基础与应用软件等领域取得更多突破，并孕育一批高成长公司。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405060948357925e720&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405060948357925e720&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2433461518","title":"昭衍新药4月30日遭北向资金减持284.24万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2433461518","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2433461518?lang=zh_cn&edition=full","pubTime":"2024-05-06 09:30","pubTimestamp":1714959026,"startTime":"0","endTime":"0","summary":"4月30日，北向资金减持昭衍新药284.24万股。截止当日收盘，沪股通共持有昭衍新药985.05万股，占流通股1.56%。沪股通减持金额前五个股分别为国电南瑞、大秦铁路、贵州茅台、伊利股份、华泰证券。昭衍新药近5个交易日下跌6.34%，沪股通累计增持61.29万股；近20个交易日下跌9.35%，沪股通累计增持141.60万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405060934298b77dc6c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405060934298b77dc6c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2432645632","title":"昭衍新药盘中异动 股价大涨5.05%报8.731港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2432645632","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2432645632?lang=zh_cn&edition=full","pubTime":"2024-05-02 14:16","pubTimestamp":1714630603,"startTime":"0","endTime":"0","summary":"2024年05月02日下午盘14时16分，昭衍新药股票出现波动，股价急速上涨5.05%。截至发稿，该股报8.731港元/股，成交量59.332万股，换手率0.50%，振幅7.58%。昭衍新药股票所在的生物技术行业中，整体涨幅为1.66%。消息层面，截至14时16分，昭衍新药股票正面舆情新闻比例12.5%。该信息摘要如下：4月29日晚，国内CRO龙头昭衍新药发布2024年一季度业绩报告。但随着支持政策陆续出台，上游创新药企业整体回暖，将有望带动CRO迎来周期拐点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405021416437a57e7c9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405021416437a57e7c9&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431239975","title":"昭衍新药：在审议该事项时，关联董事进行了回避，可查阅当天同时披露的董事会决议公告，","url":"https://stock-news.laohu8.com/highlight/detail?id=2431239975","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431239975?lang=zh_cn&edition=full","pubTime":"2024-04-30 17:01","pubTimestamp":1714467681,"startTime":"0","endTime":"0","summary":"投资者：董秘您好，请转达黄总：贵公司目前港股折价严重，港股市值58亿元，0.7PB，严重低于净资产，而公司账面几十亿资金闲置理财，公司应该向其他优秀公司学习，在低位回购港股，待未来股价回升可增发港股融资，请重视港股融资平台，全力提升公司的投资价值，谢谢。在审议该事项时，关联董事进行了回避，可查阅当天同时披露的董事会决议公告，谢谢关注。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301702328b659633&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301702328b659633&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431360023","title":"4月30日昭衍新药跌9.99%，嘉实新收益混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2431360023","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431360023?lang=zh_cn&edition=full","pubTime":"2024-04-30 16:14","pubTimestamp":1714464898,"startTime":"0","endTime":"0","summary":"证券之星消息，4月30日昭衍新药跌9.99%，收盘报16.39元，换手率5.4%，成交量34.05万手，成交额5.69亿元。重仓昭衍新药的公募基金请见下表：该股最近90天内共有12家机构给出评级，买入评级8家，增持评级4家；过去90天内机构目标均价为20.39。根据2024基金Q1季报公募基金重仓股数据，重仓该股的公募基金共6家，其中持有数量最多的公募基金为嘉实新收益混合。该公募基金现任基金经理为胡涛 王凯。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301623278b656cd5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301623278b656cd5&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431967380","title":"昭衍新药-9.99%跌停，总市值122.91亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431967380","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2431967380?lang=zh_cn&edition=full","pubTime":"2024-04-30 11:21","pubTimestamp":1714447313,"startTime":"0","endTime":"0","summary":"4月30日，昭衍新药盘中-9.99%跌停，截至11:16，报16.39元/股，成交4.98亿元，换手率4.72%，总市值122.91亿元。截至3月31日，昭衍新药股东户数7.42万，人均流通股1.01万股。2024年1月-3月，昭衍新药实现营业收入3.25亿元，同比减少12.07%；归属净利润-2.72亿元，同比减少244.98%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301121588b647e30&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301121588b647e30&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431380633","title":"异动快报：昭衍新药（603127）4月30日11点18分触及跌停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2431380633","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431380633?lang=zh_cn&edition=full","pubTime":"2024-04-30 11:20","pubTimestamp":1714447233,"startTime":"0","endTime":"0","summary":"证券之星4月30日盘中消息，11点18分昭衍新药触及跌停板。目前价格16.39，下跌9.99%。其所属行业医疗服务目前下跌。领涨股为诺泰生物。该股为创新药，医药，基因编辑概念热股，当日创新药概念上涨0.66%，医药概念上涨0.6%，基因编辑概念上涨0.2%。4月29日的资金流向数据方面，主力资金净流入1056.39万元，占总成交额2.87%，游资资金净流出2985.98万元，占总成交额8.1%，散户资金净流入1929.6万元，占总成交额5.24%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024043000024351.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431800232","title":"港股异动 | 昭衍新药(06127)跌超11% 实验猴减值影响扩大 公司首季同比由盈转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2431800232","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2431800232?lang=zh_cn&edition=full","pubTime":"2024-04-30 09:48","pubTimestamp":1714441686,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，昭衍新药(06127)跌超11%，截至发稿，跌11.12%，报8.79港元，成交额1428.72万港元。消息面上，昭衍新药发布2024年一季报，报告期内公司实现总营收3.25亿元，同比下降12.07%；净亏损2.72亿元，同比由盈转亏。公司在财报中将亏损归因于生物资产市价波动和实验室服务业务亏损。其一，生物资产公允价值变动带来净亏损为2.84亿元。其二，实验室服务业务导致亏损2104.37万元，同比下降130.01%。实验室服务业务净亏损主要源于竞争加剧，毛利率下滑带来的影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1116042.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431800314","title":"昭衍新药大跌5.05% 2024年一季度财报不佳","url":"https://stock-news.laohu8.com/highlight/detail?id=2431800314","media":"智选洞察","top":-1,"share":"https://www.laohu8.com/m/news/2431800314?lang=zh_cn&edition=full","pubTime":"2024-04-30 09:31","pubTimestamp":1714440687,"startTime":"0","endTime":"0","summary":"04月30日，昭衍新药股价大幅下跌，截至09点31分，昭衍新药下跌5.05%，报17.29元/股，成交4685万元，换手率0.42%，振幅3.40%。资金动向截止发稿，昭衍新药获得主力净流出279万元，其中超大单流出292万元，大单流入14万元。北向资金方面，昭衍新药04月29日获得北向资金增持155.89万股，连续3日增持，截至04月29日，北向资金当前共持有昭衍新药1269.29万股，市值2.19亿元，持股占流通股比为2.01%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404300938387a578644&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404300938387a578644&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431180789","title":"昭衍新药盘中异动 快速下跌6.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431180789","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2431180789?lang=zh_cn&edition=full","pubTime":"2024-04-30 09:30","pubTimestamp":1714440612,"startTime":"0","endTime":"0","summary":"2024年04月30日早盘09时30分，昭衍新药股票出现异动，股价快速跳水6.87%。昭衍新药股票所在的生物技术行业中，整体涨幅为0.95%。消息层面，截至09时30分，昭衍新药股票正面舆情新闻比例15.38%。该信息摘要如下：4月29日晚，国内CRO龙头昭衍新药发布2024年一季度业绩报告。但随着支持政策陆续出台，上游创新药企业整体回暖，将有望带动CRO迎来周期拐点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240430093013861ea2b5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240430093013861ea2b5&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431170438","title":"图解昭衍新药一季报：第一季度单季净利润同比减244.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431170438","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431170438?lang=zh_cn&edition=full","pubTime":"2024-04-30 02:12","pubTimestamp":1714414356,"startTime":"0","endTime":"0","summary":"证券之星消息，昭衍新药2024年一季报显示，公司主营收入3.25亿元，同比下降12.07%；归母净利润-2.72亿元，同比下降244.98%；扣非净利润-2.81亿元，同比下降251.92%；负债率17.87%，投资收益697.2万元，财务费用-2801.15万元，毛利率32.84%。财报数据概要请见下图: 以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024043000002982.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431723852","title":"昭衍新药(603127.SH)发布一季度业绩，净亏损2.72亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431723852","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2431723852?lang=zh_cn&edition=full","pubTime":"2024-04-29 20:55","pubTimestamp":1714395337,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昭衍新药(603127.SH)披露2024年第一季度报告，报告期公司实现营收3.25亿元，同比下降12.07%;归母净利润亏损2.72亿元;扣非净利润亏损2.81亿元。基本每股收益-0.36元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1115030.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431832346","title":"昭衍新药(06127)一季度归母净亏损2.72亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431832346","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2431832346?lang=zh_cn&edition=full","pubTime":"2024-04-29 19:12","pubTimestamp":1714389128,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昭衍新药(06127)发布2024年度第一季度报告，营业收入3.25亿元(人民币，下同)，同比下降12.07%;归属于上市公司股东的净亏损2.72亿元，上年同期利润1.88亿元;基本每股亏损0.36元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1114695.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431267870","title":"昭衍新药大幅上涨 益诺思提交科创板IPO注册","url":"https://stock-news.laohu8.com/highlight/detail?id=2431267870","media":"智选洞察","top":-1,"share":"https://www.laohu8.com/m/news/2431267870?lang=zh_cn&edition=full","pubTime":"2024-04-29 10:40","pubTimestamp":1714358438,"startTime":"0","endTime":"0","summary":"04月29日，昭衍新药股价大幅上涨，截至10点40分，昭衍新药上涨5.07%，报18.25元/股，成交1.99亿元，换手率1.77%。消息解读上海益诺思生物技术股份有限公司申请上交所科创板IPO审核状态变更为“提交注册”。最新财报显示，今年年报，昭衍新药实现营业收入23.76亿元，同比增长4.78%，净利润为3.97亿元，同比减少63.04%，基本每股收益为0.53元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404291105247924ac47&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404291105247924ac47&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431053049","title":"昭衍新药4月26日获北向资金加仓205.06万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2431053049","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2431053049?lang=zh_cn&edition=full","pubTime":"2024-04-29 09:30","pubTimestamp":1714354229,"startTime":"0","endTime":"0","summary":"4月26日, 北向资金增持昭衍新药205.06万股。截止当日收盘，沪股通共持有昭衍新药1113.40万股，占流通股1.76%。沪股通增持金额前五个股分别为招商银行、贵州茅台、兴业银行、药明康德、三一重工。昭衍新药近5个交易日上涨3.52%，沪股通累计增持182.23万股；近20个交易日下跌5.34%，沪股通累计增持225.97万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042909351987bca56c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042909351987bca56c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430293136","title":"南向资金4月25日净买入昭衍新药20.82万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2430293136","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430293136?lang=zh_cn&edition=full","pubTime":"2024-04-26 09:31","pubTimestamp":1714095092,"startTime":"0","endTime":"0","summary":"4月25日, 南向资金增持昭衍新药20.82万股，连续3日增持。截止当日收盘，港股通共持有昭衍新药3884.50万股，占流通股32.63%。昭衍新药近5个交易日下跌3.14%，港股通累计增持57.33万股；近20个交易日上涨1.20%，港股通累计增持166.15万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404260943198b54fb1d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404260943198b54fb1d&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2017-08-25","address":"北京市大兴区北京经济技术开发区荣京东街甲5号","stockEarnings":[{"period":"1week","weight":-0.0634},{"period":"1month","weight":-0.0935},{"period":"3month","weight":-0.0115},{"period":"6month","weight":-0.3749},{"period":"1year","weight":-0.5313},{"period":"ytd","weight":-0.3087}],"companyName":"北京昭衍新药研究中心股份有限公司","boardCode":"AI0073","perCapita":"--","boardName":"研究和试验发展","registeredCapital":"74988万元","compareEarnings":[{"period":"1week","weight":0.0274},{"period":"1month","weight":0.0209},{"period":"3month","weight":0.1134},{"period":"6month","weight":0.0317},{"period":"1year","weight":-0.0657},{"period":"ytd","weight":0.0437}],"survey":"　　北京昭衍新药研究中心股份有限公司主营业务专注于药物全生命周期的安全性评价和监测服务，其药物临床前研究服务为公司的核心业务，主要内容包括药物非临床安全性评价服务、药效学研究服务、动物药代动力学研究服务和药物筛选。公司是中国首家通过美国FDAGLP检查，并同时具有AAALAC（国际实验动物福利审查认证协会）认证和中国CFDA的GLP认证资质的专业新药临床前安全性评价机构。所提供的试验报告和安全性数据已被美国FDA和国际上其他国家药监机构以及中国CFDA认可并用以支持在各自国家所开展的临床研究。","serverTime":1714970690088,"listedPrice":12.51,"stockholders":"0人","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"昭衍新药(603127)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供昭衍新药(603127)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"昭衍新药,603127,昭衍新药股票,昭衍新药股票老虎,昭衍新药股票老虎国际,昭衍新药行情,昭衍新药股票行情,昭衍新药股价,昭衍新药股市,昭衍新药股票价格,昭衍新药股票交易,昭衍新药股票购买,昭衍新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"昭衍新药(603127)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供昭衍新药(603127)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}